Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025 with a presentation and fireside chat starting at 2:15 p.m. PT / 5:15 p.m. ET. The event will be available via a live webcast on the company investor website.
A replay will be posted approximately two hours after the call and archived on the company website for about 90 days. Esperion is a commercial-stage biopharmaceutical company marketing two oral, once-daily non-statin LDL-C therapies, with global approvals in >40 countries and a pipeline focused on ACLY biology and treatments for primary sclerosing cholangitis and renal diseases.
Details
News Market Reaction – ESPR
On Jan 5, the day this news came out, ESPR closed 2.70% above the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Conference date
- January 14, 2025
- Esperion presentation and fireside chat
- Presentation time PT
- 2:15 p.m. PT
- Start of presentation and fireside chat
- Presentation time ET
- 5:15 p.m. ET
- Start of presentation and fireside chat
- Webcast archive period
- approximately 90 days
- Replay availability on company website
- Marketed therapies
- two oral once-daily therapies
- Non-statin LDL-C lowering products
- Global approvals
- more than 40 countries
- Geographic reach of marketed products
Historical Context
-
ACC statement recommending bempedoic acid for PAD patients with diabetes.
-
Equity awards to new CCO and employees under inducement plan.
-
Otsuka launch of NEXLETOL in Japan with near-term payment and royalties.
-
Piper Sandler healthcare conference presentation and webcast details.
-
Health Canada approval of NILEMDO for LDL‑cholesterol reduction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cardiometabolic medical
orphan disease medical
acly biology medical
low-density lipoprotein cholesterol (LDL-C) medical
primary sclerosing cholangitis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025.
The company’s presentation and participation in a fireside chat will begin at 2:15 p.m. PT/5:15 p.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.